Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219165 | 0.85 | HSP90AA1 (0.40) | PDE10AMAPTALDH1A1LMNATRPV4 | |
| SCHEMBL1629643 | 0.85 | NR3C2 (0.39) | PDE10AMAPTALDH1A1LMNATRPV4 | |
| SCHEMBL27675323 | 0.82 | NR3C2 (0.37) | PDE10AMAPTALDH1A1LMNATRPV4 | |
| SCHEMBL1628852 | 0.80 | ALK (0.41) | PDE10AMAPTALDH1A1LMNASCN9A | |
| SCHEMBL12722869 | 0.80 | PDE10A (0.49) | PDE10AMAPTALDH1A1LMNAATM | |
| SCHEMBL1629555 | 0.79 | PDE10A (0.48) | PDE10AMAPTALDH1A1LMNAATM | |
| SCHEMBL12722811 | 0.78 | PDE10A (0.48) | PDE10AMAPTALDH1A1LMNAATM | |
| SCHEMBL14378206 | 0.76 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL1630418 | 0.75 | HSP90AA1 (0.41) | PDE10AMAPTALDH1A1LMNA | |
| SCHEMBL1628788 | 0.75 | HSP90AA1 (0.41) | PDE10AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-7906657-B2 | 1,5-diphenylpyrazoles II as HSP90 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20110028485-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | EGGENWEILER HANS-MICHAEL | 2011-02-03 | — | — | US | disclosed |
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | PDE10A 3712/4885MAPT 2046/4885ALDH1A1 979/4885 |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | PDE10A 3756/4885MAPT 2299/4885ALDH1A1 777/4885 |
| US-20110028485-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | PDE10A 3712/4885MAPT 2046/4885ALDH1A1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.